Here are three takeaways:
1. The four abstracts were titled:
- “Multifocal Nitrous Oxide Cryoballoon Ablation With or Without Endoscopic Mucosal Resection (EMR) for Treatment of Neoplastic Barrett’s Esophagus (BE): Preliminary Results of a Prospective Trial in Treatment-Naive and Previously Ablated Patients”
- “Nitrous Oxide Cryotherapy for Treatment of Esophageal Squamous Cell Neoplasia (ESCN): Initial Multicenter International Experience with a Novel Portable Cryoballoon Focal Ablation System (CbFAS)”
- “Efficacy and Safety of the CryoBallon Focal Ablation System (CBFAS) for the Eradication of Dysplastic Barrett’s Esophagus Islands”
- “Use of the Cryoballoon Focal Ablation System for the Eradication of Esophageal Neoplasia: A Single-Center Experience”
2. The CryoBalloon Focal Ablation System is a through-the-scope device that an inert refrigerant simultaneously inflates and cools from a small disposable handheld unit.
3. Founded in 2007, C2 Therapeutics is a medical device company focused on improving methods of eliminating unwanted tissue in endoscopic applications.
More articles on GI & endoscopy:
EndoChoice releases RescueNet retrieval device: 4 points
33 winners of AGA Research Foundation’s 2016 awards
Northwestern Medicine Digestive Health Foundation raises $1.2M: 3 notes
